Theravance Biopharma (NASDAQ:TBPH) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16), Zacks reports. The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same quarter in the previous year, the firm posted ($0.17) earnings per share.

Theravance Biopharma Price Performance

Shares of TBPH stock traded down $0.13 on Thursday, hitting $9.55. The company’s stock had a trading volume of 23,799 shares, compared to its average volume of 344,891. The stock has a market capitalization of $467.21 million, a price-to-earnings ratio of -9.58 and a beta of 0.25. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $11.71. The firm’s fifty day moving average price is $8.36 and its 200-day moving average price is $8.69.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. TD Cowen reduced their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.75.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 322,743 shares in the company, valued at approximately $2,904,687. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.